Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Veru Inc

VERU
Current price
0.63 USD +0.0099 USD (+1.60%)
Last closed 0.66 USD
ISIN US92536C1036
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 107 182 368 USD
Yield for 12 month -40.67 %
1Y
3Y
5Y
10Y
15Y
VERU
21.11.2021 - 28.11.2021

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Address: 2916 North Miami Avenue, Miami, FL, United States, 33127

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

3.4 USD

P/E ratio

Dividend Yield

Current Year

+16 296 958 USD

Last Year

+16 296 958 USD

Current Quarter

+3 953 870 USD

Last Quarter

+4 135 301 USD

Current Year

+7 565 928 USD

Last Year

+7 565 928 USD

Current Quarter

+1 338 015 USD

Last Quarter

+678 299 USD

Key Figures VERU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -65 041 396 USD
Operating Margin TTM -279.44 %
PE Ratio
Return On Assets TTM -64.36 %
PEG Ratio
Return On Equity TTM -126.72 %
Wall Street Target Price 3.4 USD
Revenue TTM 14 091 909 USD
Book Value 0.26 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 18.3 %
Dividend Yield
Gross Profit TTM 30 591 388 USD
Earnings per share -0.3 USD
Diluted Eps TTM -0.3 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -265.42 %

Dividend Analytics VERU

Dividend growth over 5 years

Continuous growth

3 years

Payout Ratio 5 years average

Dividend History VERU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 28.04.2014
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 07.05.2014

Stock Valuation VERU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 117.6471
Enterprise Value Revenue 6.5079
Price Sales TTM 7.606
Enterprise Value EBITDA -3.2346
Price Book MRQ 2.849

Financials VERU

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators VERU

For 52 weeks

0.36 USD 1.92 USD
50 Day MA 0.82 USD
Shares Short Prior Month 12 873 914
200 Day MA 0.88 USD
Short Ratio 20.88
Shares Short 12 540 637
Short Percent 9.59 %